Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Congenital Prothrombin Deficiency Publisher



Daneshi M1 ; Naderi T2 ; Tabibian S3 ; Shams M3 ; Rashidpanah J4 ; Dorgalaleh A3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Laboratory Sciences, School of Allied Medicine, Arak University of Medical Sciences, Arak, Iran
  2. 2. Department of Hematology and Blood Transfusion, School of Allied Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Cellular and Molecular Anesthesia Published:2018


Abstract

Congenital prothrombin deficiency is an extremely rare hemorrhagic disorder with estimated prevalence of 1 per 2,000,000 in the general population. Since the disorder is an autosomal recessive disorder, the disorder is more frequent in areas with high rate of consanguinity. Clinical manifestations of the disorder are highly variable ranging from mild bleeding episodes to severe life-threatening hemorrhages. The disorder can be diagnosed based on routine and specific tests. Deficiency in concentration of specific factor II (FII) is available, but patients can receive fresh frozen plasma (FFP) and prothrombin complex concentrate (PCC). Traditionally patients with prothrombin deficiency receive on-demand therapy, but secondary prophylaxis can be used for those patients with high risk of severe life-threatening bleeding. With timely diagnosis and appropriate management of disorder quality of life in these patients can significantly improve. © 2018 Shahid Beheshti University of Medical Sciences, Anesthesiology Research Center. All rights reserved.